Dr David Hughes, MEng, DPhil
Chief Executive Officer
Dr Hughes was appointed CEO of CN Bio in 2018, having previously served the company as Chief Technical Officer and Head of Engineering. He led CN Bio’s $9m 2020 Series A fundraise and has grown the company into a market leader in organ-on-a-chip, a technology set to radically improve the efficiency of drug discovery in the next decade.
Dr Hughes is a noted innovator in the field and led the company’s participation in a key five-year $26M DARPA contract alongside the Massachusetts Institute of Technology to build a human body-on-a-chip. He holds a Masters in Engineering Science and a Doctorate in Chemical Engineering from the University of Oxford.
Dr Paul Brooks, MBA, PhD
Chief Business Officer
Dr Brooks joined CN Bio Innovations in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Dr Tomasz Kostrzewski, PhD
VP – Science and Technology
Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academic, pharma, and regulators. In 2021 he was subsequently promoted to VP – Science and Technology with responsibility for all technical activities including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.
Emily Drea, LLB
Emily Drea joined CN Bio in January 2022 having worked as an in-house lawyer for 10 years at Arm Limited and more recently as Head of Legal at Pelion. Whilst at Arm, Emily held multiple roles which included supporting commercial transactions on a global level, performing numerous product counsel roles, advising on IP licensing issues, and working in collaboration with senior management on the areas of risk management and compliance. At Pelion, Emily led the legal function as it divested from Arm Limited and became its own separate legal entity. Emily is responsible for providing the legal support CN Bio needs to enable it to grow and scale. Emily also holds a Post Graduate Diploma in Intellectual Property Law and Practice from the University of Oxford.
Zoe Masey, FCCA, MBA
Zoe Masey joined CN Bio in September 2020 with over 20 years of experience and is responsible for a broad portfolio of Financial & Operational matters. Having worked globally, (being based in the UK and UAE) and across a range of industries, she has led the finance operations for a leading AIM-listed consultancy firm in the Middle East and developed business expansion strategies for a successful start-up.
Zoe is a Fellow Member of the Association of Chartered Certified Accountants and holds an MBA from Oxford Brookes University.
Maureen Coleman, BSc
Maureen Coleman has amassed over 30 years of experience within the pharmaceutical industry, latterly as VP Global Strategy Development for GlaxoSmithKline. Since 2007 she has been working with a number of investor-backed companies including as founding Chief Executive of NovaThera, a regenerative medicine spin-out from Imperial College London, and as Non-Executive Director and Chairman of life science spin-out companies from Oxford, Kings College Universities and other life science entrepreneurs.
Maureen is currently Chairman of Parafricta Ltd, a wound care specialist materials company, and CN Bio Innovations – the human organ-on-a-chip technology company whose LiverChip® and Quantum B® human liver models are being well received as a disruptive route to liver modeling for Hepatitis B drug discovery and ADME tox testing. She is a founding Director of MedInnovate Ltd, a technology consultancy spanning the healthcare industry, and a founding industry consulting partner at Kinapse Ltd.
Dr David Scales, PhD, LLM, FRCPath
Dr Scales has broad experience in the pharmaceutical, biotech and contract research sectors in senior and non-executive roles. During more than 20 years working for large pharmaceutical companies, Dr Scales’ roles included International VP at GlaxoWellcome overseeing development staff located in the USA, UK, Italy, and Japan. During his tenure at GlaxoWellcome he represented the European pharmaceutical Industry and chaired the Safety Committee for the first two International Conferences on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Dr Scales moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd, Charterhouse Therapeutics Ltd, and Antisoma PLC before becoming CEO of Cerogenix Ltd and then GlycoForm Ltd. In January 2013 he joined CN Bio Innovations as Chief Executive. He took on the role as Board advisor to the company in 2016 to then join as Non-Executive Director in 2018. Dr Scales initially trained as a toxicological pathologist, holds three degrees from London University and the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Pathologists.